Participation in U.S. National Cancer Institute (NCI)-funded clinical trials is on the downswing, driven by a staffing shortage. Now, the agency is turning to remote work in hopes of boosting patient ...

Foundation Medicine is one of the chief contributors to ComboMATCH, an initiative to test biomarker-targeted cancer treatment combinations ...

The study is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and conducted by the NCI funded Experimental Therapeutics Clinical Trials Network, under ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

The authors conclude, "improvements in trial initiation should encourage potential partners in the pharmaceutical and biotechnology industries to view the NCI's publicly funded clinical trials system ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

MADRID, Spain and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop ...

Using Indirect Comparisons of Prospective, Randomized Trials to Make Therapeutic Decisions in Melanoma: Cross-Trial Comparisons as Surrogates for Proper Head-To-Head Studies? Clinical trials are ...

Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine ...

Charles Peyton, M.D. associate professor in the UAB Department of Urology, has been selected as a recipient of the highly competitive 2025 NCI Early Career Cancer Clinical Investigator Award (ECIA).